Fast mov­ing Chi­nese reg­u­la­tors wave third home­grown PD-1 to mar­ket

Jiang­su Hen­grui has se­cured an OK for its PD-1 drug, mark­ing the fifth PD-1 ap­proval in Chi­na and tilt­ing the scale to­ward home­grown check­points.

Hen­grui — a top 25 bio­phar­ma com­pa­ny glob­al­ly led by Piaoyang Sun — joins Jun­shi and In­novent in fac­ing for­eign coun­ter­parts: Mer­ck’s Keytru­da and Bris­tol My­ers’ Squibb’s Op­di­vo.

Its drug, cam­re­lizum­ab, has long been tapped as one of the first fin­ish­ers in Chi­na’s heat­ed check­point race. In­cyte dished out $25 mil­lion plus $770 mil­lion in biobucks to part­ner on its PD-1, al­though an odd ad­verse re­ac­tion di­min­ished the Amer­i­can biotech’s en­thu­si­asm.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN